Animal, Human Studies Support InSea2 for Diabetes Management
InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.
InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.
In the first study, published in Food Research International, in vitro experiments demonstrated InSea2’s mechanism of action against alpha-amylase and alpha-glucosidase. An in vivo experiment on laboratory animals also demonstrated InSea2’s ability to increase postprandial blood sugar by 90% while reducing insulin secretion by 40%.
InSea2 was also the focus of a human trial published in Applied Physiology, Nutrition, and Metabolism in which consumption of the ingredient complex significantly lowered postprandial blood glucose response by 48% and insulin secretion by 12%. InnoVactiv states that insulin sensitivity was also increased by 12% in the trial.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
